Telik, Inc. Company Description
Go Telik on the mountain: Telik discovers new drugs, focusing mainly on new treatments for cancer. The company uses its proprietary Target-Related Affinity Profiling (TRAP) technology to identify potential drug compounds by analyzing the way they interact with proteins. Lead drug candidate Telcyta targets chemotherapy-resistant tumors and is undergoing clinical trials for several kinds of cancer, including ovarian and non-small cell lung cancers. Another candidate, Telintra, may treat blood disorders, including neutropenia and myelodysplastic syndrome. Telik has a host of other anticancer compounds at earlier stages of development.
View the Comprehensive Company Description for Telik, Inc.
The Company Description provides a historical perspective of Telik, Inc.'s organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Telik, Inc.'s evolution in the marketplace.
